Conditionally MYC: insights from novel transgenic models

Constadina Arvanitis1, Dean W Felsher

  • 1Departments of Medicine and Pathology, Division of Oncology, School of Medicine, Stanford University, CCSR 1105B, 269 Campus Drive, Stanford, CA 94305-5151, USA.

Cancer Letters
|July 26, 2005
PubMed

Insights

MYC oncogene inactivation can reverse cancer development. Recent studies show targeting MYC offers a promising and effective cancer treatment strategy across various cancer types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MYC is a well-known oncogene implicated in numerous cancers.
  • Its role in cancer pathogenesis has been recognized for decades.
  • The therapeutic potential of targeting MYC remained uncertain until recently.

Purpose of the Study:

  • To review experimental evidence on MYC inactivation as a cancer therapy.
  • To assess the efficacy and specificity of targeting MYC.

Main Methods:

  • Review of recent experimental model systems.
  • Analysis of data from conditional transgenic models demonstrating MYC inactivation.

Main Results:

  • Brief inactivation of MYC can lead to the reversal of established tumorigenesis.
  • Experimental models show MYC inactivation is feasible and effective.

Conclusions:

  • Targeting MYC represents a specific and effective therapeutic strategy for many cancers.
  • Further research into MYC-targeted therapies is warranted.